Tascini Carlo, Giuliano Simone, Attanasio Vittorio, Segreti Luca, Ripoli Andrea, Sbrana Francesco, Severino Sergio, Sordelli Chiara, Weisz Sara Hana, Zanus-Fortes Agnese, Leanza Gabriele Maria, Carannante Novella, Di Cori Andrea, Bongiorni Maria Grazia, Zucchelli Giulio, De Vivo Stefano
Infectious Diseases Clinic, Department of Medicine (DAME), University of Udine, 33100 Udine, Italy.
Infectious Diseases Clinic, Azienda Sanitaria Universitaria del Friuli Centrale (ASUFC), 33100 Udine, Italy.
Antibiotics (Basel). 2023 Jun 2;12(6):1001. doi: 10.3390/antibiotics12061001.
(1) Background: Infections are among the most frequent and life-threatening complications of cardiovascular implantable electronic device (CIED) implantation. The aim of this study is to compare the outcome and safety of a single-procedure device extraction and contralateral implantation versus the standard-of-care (SoC) two-stage replacement for infected CIEDs. (2) Methods: We retrospectively included 66 patients with CIED infections who were treated at two Italian hospitals. Of the 66 patients enrolled in the study, 27 underwent a single procedure, whereas 39 received SoC treatment. All patients were followed up for 12 months after the procedure. (3) Results: Considering those lost to follow-up, there were no differences in the mortality rates between the two cohorts, with survival rates of 81.5% in the single-procedure group and 84.6% in the SoC group ( = 0.075). (4) Conclusions: Single-procedure reimplantation associated with an active antibiofilm therapy may be a feasible and effective therapeutic option in CIED-dependent and frail patients. Further studies are warranted to define the best treatment regimen and strategies to select patients suitable for the single-procedure reimplantation.
(1) 背景:感染是心血管植入式电子设备(CIED)植入术后最常见且危及生命的并发症之一。本研究旨在比较单次手术取出设备并对侧植入与标准治疗(SoC)两阶段更换感染CIED的疗效和安全性。(2) 方法:我们回顾性纳入了在两家意大利医院接受治疗的66例CIED感染患者。在纳入研究的66例患者中,27例接受了单次手术,而39例接受了SoC治疗。所有患者在术后均随访12个月。(3) 结果:考虑到失访情况,两组队列的死亡率无差异,单次手术组的生存率为81.5%,SoC组为84.6%(P = 0.075)。(4) 结论:对于依赖CIED且身体虚弱的患者,单次手术再植入联合主动抗生物膜治疗可能是一种可行且有效的治疗选择。有必要进一步研究以确定最佳治疗方案和选择适合单次手术再植入患者的策略。